EcoDrugPlus

Antithrombin-Iii-Like

Ensembl ID : ENSOTSG00005023767
Gene Symbol: LOC112250696
3 Cross references
195 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSOTSG00005022686
Gene Symbol: LOC112249028
3 Cross references
171 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSOTSG00005040622
Gene Symbol: LOC112215344
3 Cross references
160 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSOTSG00005017046
Gene Symbol: LOC112227752
3 Cross references
160 Possible Orthologues:

Apoptosis Regulator Bcl-2-Like

Ensembl ID : ENSOTSG00005025476
Gene Symbol: LOC112215344
3 Cross references
160 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSOTSG00005001706
Gene Symbol: APEX1
3 Cross references
208 Possible Orthologues:

Arachidonate 12-Lipoxygenase

Ensembl ID : ENSOTSG00005036966
Gene Symbol: ALOX12
1 Cross references
191 Possible Orthologues:

Arachidonate 5-Lipoxygenase A

Ensembl ID : ENSOTSG00005033730
Gene Symbol: ALOX5A
1 Cross references
220 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSOTSG00005024096
Gene Symbol: ALOX5AP
1 Cross references
194 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Activating Protein

Ensembl ID : ENSOTSG00005019344
Gene Symbol: ALOX5AP
1 Cross references
194 Possible Orthologues:

Arachidonate 5-Lipoxygenase-Like

Ensembl ID : ENSOTSG00005019757
Gene Symbol: LOC112253187
3 Cross references
219 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSOTSG00005004593
Gene Symbol: AVPR1A
1 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).